Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Ana Marin Niebla, Eva Gine, Mariana Bastos-Oreiro, Amanda Perez, Alba Cabirta, Fatima De la Cruz Vicente, Marta Canelo Vilaseca, Ana Jiménez Ubieto, Sonia González De Villambrosia, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Pilar Gomez Prieto, Raul Cordoba, Ana Saus Carreres, Alejandro Martin Garcia-Sancho, Ana Maria Garcia-Noblejas Moya, Carlos Grande, Pablo Prieto Martínez, Concepción Nicolás, Antonio Gutierrez, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Maria Teresa Villalobos, Tomas García-Cerecedo, Rosalia Alonso Trillo, Eva Donato, Paola Villafuerte Gutiérrez, Daniel García Belmonte, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Juan-Manuel Sancho, Beatriz De La Cruz, Raja Prince-Eladnani, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3592.

https://doi.org/10.1182/blood-2025-3592

Published: 2025

Journal Articles

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Mariana Bastos-Oreiro, Alba Cabirta, Amanda Perez, Ana Saus Carreres, Sonia González De Villambrosia, Marta Canelo, Ana Maria Garcia-Noblejas Moya, Beatriz De La Cruz Benito, Paola Villafuerte Gutiérrez, Fatima De la Cruz Vicente, Juan Carlos Caballero, Ana Jiménez-Ubieto, Daniel García Belmonte, Ana Muntanola Prat, Eva Gonzalez Barca, Hugo Daniel Luzardo Henríquez, Eduardo Rios Herranz, Alejandro Martin Garcia-Sancho, Carlos Grande, Concepción Nicolás, Antonio Gutierrez, Marina Gomez-Llobell, Jose Angel Hernandez Rivas, Blanca Sánchez-González, Ainara Ferrero Campos, Rosalia Alonso Trillo, Eva Donato, Silvia Rocio Verdesoto Cozzarelli, Sandra Suarez Ordoñez, Emilia Pardal De La Mano, Pilar Gomez Prieto, Amparo Avaría, Lucia Villalon Blanco, Alicia Roldán-Pérez, Raul Cordoba, Juan-Manuel Sancho, Eva Gine, Víctor Navarro Garces, Pau Abrisqueta, Ana Marin Niebla

Blood (2025) 146 (Supplement 1): 3585.

https://doi.org/10.1182/blood-2025-3585

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Blood (2025) 146 (Supplement 1): 899.

https://doi.org/10.1182/blood-2025-899

Published: 2025

Journal Articles

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Blood (2025) 146 (Supplement 1): 782.

https://doi.org/10.1182/blood-2025-782

Published: 2025

Journal Articles

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Blood (2025) 146 (Supplement 1): 5350.

https://doi.org/10.1182/blood-2025-5350

Published: 2025

Journal Articles

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

Blood (2025) 146 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2025-5322

Published: 2025

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Angel Serna, Gloria Iacoboni, Anna Aguilera Romero, Victor Navarro, Carolina Martinez, Pablo Manresa, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramos, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernández-Caldas, Ruben Fernandez Alvarez, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Iñigo Olazabal, Izaskun Zeberio, Cristina Barrenetxea Lekue, Diego Clavo-Martín, Samuel Romero Dominguez, Sofia Martin-Consuegra, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Alejandro Martin Garcia-Sancho, Mariana Bastos-Oreiro, Pau Abrisqueta

Blood (2025) 146 (Supplement 1): 3737.

https://doi.org/10.1182/blood-2025-3737

Published: 2025

Journal Articles

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort

Jose Tomas Navarro, Ana Jiménez Ubieto, Araceli Rubio Martinez, Alejandro Martin Garcia-Sancho, Eva Gonzalez Barca, Pablo Lorente, Paloma Garcia Martin, Guillermo Rodríguez Garcia, Manuel Espeso De Haro, Antonio Gutierrez, Angel Ramirez, Inigo Olazabal Eizaguirre, Antonio Garcia, Xavier Cintas, Andres Gonzalez Garcia, Santiago Montes-Moreno

Blood (2025) 146 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2025-3006

Published: 2025

Journal Articles

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Blood (2025) 146 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2025-1233

Published: 2025

Journal Articles

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Blood (2025) 146 (Supplement 1): 472.

https://doi.org/10.1182/blood-2025-472

Published: 2025

Journal Articles

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

Mariana Bastos-Oreiro, Gloria Iacoboni, Pablo Manresa, Carolina Martinez, Laura Magnano, Ana Jiménez Ubieto, Sofía Vázquez-Díaz, Maria Jose Rodriguez Salazar, Maria Teresa Busnego Barreto, Raquel Del Campo, Pedro José Paúl Vidaller, Ilda Murillo, Eva Donato, Angel Serna, Hugo Daniel Luzardo Henríquez, Pilar Gomez Prieto, Elena Perez Ceballos, Begona Mendibil, Sergio Ramons, Ana Maria Garcia-Noblejas Moya, Sonia González De Villambrosia, Francisco Javier Diaz Galvez, Javier Lopez Jimenez, Paula Fernandez-Caldas, Antonio Gutierrez, Blanca Sanchez, Nazaret Dominguez, María Civeira Marin, Paola Villafuerte Gutiérrez, Izaskun Zeberio, Irati Ormezabal, Cristina Barrenetxea Lekue, Norma Gutiérrez, Sofia Martin-Consuegra, Samuel Romero Dominguez, Sofia Huerga, Nuria Golbano, Rosalia Riazza, Jose Antonio Hueso García, Pilar Martinez-Barranco, Belen Navarro Matilla, Lucia Villalon Blanco, Paula Ortega Nadal, Ana Torres Tienza, Víctor Navarro Garces, Pau Abrisqueta, Alejandro Martin Garcia-Sancho

Blood (2025) 146 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2025-2732

Published: 2025

Journal Articles

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Blood (2025) 146 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2025-3677

Published: 2025

Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Blood (2025) 146 (Supplement 1): 466.

https://doi.org/10.1182/blood-2025-466

Published: 2025

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Leyre Bento, Fernando Martín Moro, Antonio Gutierrez, Ana Jiménez Ubieto, Alberto López, Blanca Sánchez González, Belén Navarro, Alicia Segura, Mireia Franch, Ana García-Noblejas, Eva Donato, Alejandro Martín García-Sancho, Beatriz De La Cruz, Alfonso Ortiz Algarra, Roberto Trelles-Martínez, Javier López, Carlos Grande, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2024-203615

Published: 2024

Journal Articles

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Blood (2024) 144 (Supplement 1): 3414.

https://doi.org/10.1182/blood-2024-205005

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Plasmablastic lymphoma (PBL) comparison between europe - Latin America and validation of the PBL international prognostic index (PBL-IPI): Collaborative study of the lymphoma groups geltamo, gatla and gell

Comparison of infectious complications in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells vs bispecific antibodies

Spanish real-life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma: Results of a cohort of 118 patients on behalf of GELTAMO.

Uncovering molecular trajectories in follicular lymphoma using hidden markov models of ctdna dynamics

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Prognostic variables associated with the development of cytokine release syndrome after bispecific antibodies in non-Hodgkin lymphoma patients – the geltamo (Spanish Lymphoma Group) experience

Epidemiology and clinical characteristics of idiopathic multicentric castleman disease in Spain (ARCANA study): Prevalence cohort

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only